Cold-fX

Cold-fX is a ginseng-derived natural health product that is widely used in Canada for the prevention and treatment of the common cold. It is manufactured by CV Technologies, a company based in Edmonton, Alberta.

History[edit | edit source]

Cold-fX was first introduced to the Canadian market in 1996 by CV Technologies, which is now known as Afrazen Biosciences. The product was developed by Jacqueline Shan, a scientist with a background in pharmacology and Traditional Chinese Medicine.

Composition[edit | edit source]

The active ingredient in Cold-fX is a patented extract of North American ginseng (Panax quinquefolius), known as CVT-E002. This extract is standardized to contain 80% poly-furanosyl-pyranosyl-saccharides, which are believed to have immune-boosting properties.

Clinical Evidence[edit | edit source]

Several clinical trials have been conducted to evaluate the efficacy of Cold-fX in preventing and treating the common cold. These studies have generally found that Cold-fX can reduce the frequency, severity, and duration of cold symptoms, although some researchers have questioned the quality of the evidence.

Controversies[edit | edit source]

In 2007, CV Technologies was criticized for making unsubstantiated claims about the effectiveness of Cold-fX. The company was also involved in a class-action lawsuit in 2012, which alleged that it had misled consumers about the product's ability to prevent colds.